Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1994 3
1996 2
1997 1
1999 2
2001 1
2003 2
2004 2
2005 2
2006 5
2007 9
2008 7
2009 2
2010 8
2011 6
2012 3
2013 2
2014 1
2015 2
2016 2
2017 1
2018 2
2019 3
2020 3
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. Among authors: vaddi k. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L. Sloan SL, et al. Among authors: vaddi k. Blood. 2023 Sep 7;142(10):887-902. doi: 10.1182/blood.2022019419. Blood. 2023. PMID: 37267517
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Quintás-Cardama A, et al. Among authors: vaddi k. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. Blood. 2010. PMID: 20130243 Free PMC article.
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R. Hing ZA, et al. Among authors: vaddi k. Nat Commun. 2023 Jan 6;14(1):97. doi: 10.1038/s41467-022-35778-1. Nat Commun. 2023. PMID: 36609611 Free PMC article.
Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason C, Alinari L, Blaser BW, Baiocchi R. Long ME, et al. Among authors: vaddi k. Blood Adv. 2024 Jan 9;8(1):150-163. doi: 10.1182/bloodadvances.2023010554. Blood Adv. 2024. PMID: 37782774 Free PMC article.
Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions.
Zhang P, Brinton LT, Gharghabi M, Sher S, Williams K, Cannon M, Walker JS, Canfield D, Beaver L, Cempre CB, Phillips H, Chen X, Yan P, Lehman A, Scherle P, Wang M, Vaddi K, Baiocchi R, Wang R, Sampath D, Alinari L, Blachly JS, Lapalombella R. Zhang P, et al. Among authors: vaddi k. Sci Adv. 2022 Sep 16;8(37):eabp9005. doi: 10.1126/sciadv.abp9005. Epub 2022 Sep 16. Sci Adv. 2022. PMID: 36112677 Free PMC article.
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason J, Long M, Chan WK, Prouty A, Chung JH, Zhang Y, Singh S, Youssef Y, Bhagwat N, Chen Z, Chen-Kiang S, Di Liberto M, Elemento O, Sehgal L, Alinari L, Vaddi K, Scherle P, Lapalombella R, Paik J, Baiocchi RA. Brown-Burke F, et al. Among authors: vaddi k. Blood Adv. 2023 Oct 24;7(20):6211-6224. doi: 10.1182/bloodadvances.2023009906. Blood Adv. 2023. PMID: 37327122 Free PMC article.
Transgenic animals in inflammatory disease models.
Brodmerkel CM, Vaddi K. Brodmerkel CM, et al. Among authors: vaddi k. Curr Opin Biotechnol. 2003 Dec;14(6):652-8. doi: 10.1016/j.copbio.2003.10.001. Curr Opin Biotechnol. 2003. PMID: 14662397 Review.
74 results